WO2017071346A1 - 脆弱拟杆菌在抗水产病原菌中的应用 - Google Patents

脆弱拟杆菌在抗水产病原菌中的应用 Download PDF

Info

Publication number
WO2017071346A1
WO2017071346A1 PCT/CN2016/092384 CN2016092384W WO2017071346A1 WO 2017071346 A1 WO2017071346 A1 WO 2017071346A1 CN 2016092384 W CN2016092384 W CN 2016092384W WO 2017071346 A1 WO2017071346 A1 WO 2017071346A1
Authority
WO
WIPO (PCT)
Prior art keywords
bacteroides fragilis
fragilis
bacteroides
pathogenic bacteria
vibrio
Prior art date
Application number
PCT/CN2016/092384
Other languages
English (en)
French (fr)
Inventor
智发朝
白杨
王晔
刘洋洋
王从峰
Original Assignee
广州知易生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广州知易生物科技有限公司 filed Critical 广州知易生物科技有限公司
Publication of WO2017071346A1 publication Critical patent/WO2017071346A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Definitions

  • the invention relates to the field of microbial technology, in particular to the application of Bacteroides fragilis in aquaculture, in particular to the application of Bacteroides fragilis in anti-aquatic pathogens.
  • Probiotics are a kind of active microorganisms beneficial to the host. They are the general term for active beneficial microorganisms that are colonized in the human or animal gut and reproductive system and can produce exact health effects to improve the balance of the micro-ecology of the host and play a beneficial role. It functions primarily by improving the balance of the host intestinal microflora. It has the functions of improving intestinal flora structure, inhibiting pathogenic bacteria, generating nutrients, improving immunity, eliminating carcinogenic factors, lowering cholesterol and blood pressure, and improving lactose digestibility. Fuller Probiotics were first defined in 1989: "Probiotics are living bacteria additives that have a beneficial effect on the health of the host by improving the balance of the intestinal flora.”
  • Probiotics that have been widely used in human life include Clostridium acetate, Lactobacillus, Bifidobacterium, Lactobacillus acidophilus, Actinomycetes, and yeasts. With the development of microbial control methods, especially the prospect of probiotics replacing traditional antibiotics, probiotics and their preparations are increasingly being used in aquaculture. At present, probiotics and their preparations in aquaculture are mainly divided into two categories:
  • Single preparation such as yeast, photosynthetic bacteria, lactic acid bacteria, lactobacillus, lactococcus lactis, Pseudomonas fluorescens, Bacillus, etc.;
  • composite preparations such as the US bacteria, complex active biological water purification agents, etc., mainly nitrifying bacteria and denitrifying bacteria, Bacillus subtilis, lactobacilli, bifidobacteria, pseudomonas, Streptococcus faecalis, yeast, etc.
  • the composition of the strain are composed of beneficial strains that are targeted for screening, which can improve the micro-ecological balance in aquatic animals, stimulate the body's immune system, antagonize pathogenic microorganisms, and degrade organic waste, thereby reducing disease occurrence and promoting aquatic animal growth and development. Improve the ecological environment of farming.
  • probiotics have a good effect in aquaculture applications, such as multiple probiotics isolated from shrimp and other animals, so that the microbial complex liquid can improve the quality and stabilize the water quality. It is an important technology to ensure the success of farming. Since no chemical is applied, the produced aquatic product is a relatively complete and non-polluting green food, and the aquatic product can be prevented from being resistant.
  • the water body that continuously uses the bacterial liquid for many years must form the ecological advantage of the effective microbial flora, achieve a virtuous cycle of the water environment, and ensure the sustainable development of aquatic product breeding.
  • Bacteroides fragilis is an obligate anaerobic bacteria.
  • the morphology of the cells is polymorphic depending on the medium and the growth stage. Under normal conditions, the cells are rod-shaped, the ends are obtuse, and the coloration is deep. Shallow and uneven, with capsules, no spores, no power, some with vacuoles, and different lengths of bacteria.
  • Bacteroides fragilis is a part of the normal flora of human and animal gut, mainly in the colon. In addition, the respiratory tract, gastrointestinal tract and genitourinary mucosa can also colonize and grow. Bacteroides fragilis acts as a conditional pathogen.
  • the host mucosa When the host mucosa is damaged, it can invade the submucosa, cause infection, and can also flow through the blood, causing other organs of the body, such as the intestine, abdominal cavity, liver, lung, brain tissue, A purulent infection of soft tissue, bone marrow, etc., accompanied by an abscess.
  • Zhang Jijie isolated a Bacteroides strain BF839 from the well-developed infant or the intestine of a younger animal. It can be used as a live bacterial preparation to increase the growth and development of children, to prevent acute and chronic enteritis, dysbacteriosis, upper respiratory tract infection and neurological function. Symptom Good curative effect (see Chinese invention patent application with the publication number CN1056314A; and: Zhang Jijie, et al. Clinical application research of Bacteroides fragilis (BF839) bacterial liquid. Chinese Journal of Biological Products, 1995, Vol. 8, No. 2, Pages 63-65). In 2012, Zhifa Chao et al.
  • Bacteroides fragilis strain (preservative No. CGMCC NO.7280) with probiotic characteristics from infant feces, which can be used to treat inflammatory bowel disease, diarrhea, etc. (See publication number CN103146620A , CN103142658A and CN103156888A Chinese invention patent application);
  • Bd312 was found to have similar bacterial morphology, culture characteristics, physiological and biochemical reaction results to Bacteroides fragilis, and BLASTN sequence ratio
  • the homologous strain was 99% homologous to the Bacteroides fragilis standard strain ATCC25285.
  • the susceptibility test indicated that the strain Bd312 was not sensitive to cefradine, amoxicillin, gentamicin, sulfamethoxazole and trimethoprim.
  • Acute and chronic toxicity tests suggest no toxicity (see: Liu Yangyang, et al. Isolation and identification of non-toxic fragile Bacteroides in healthy infants. Chinese Journal of Medicine, 2014, Vol. 94, No. 30, pp. 2372-2374). However, there are no reports on the application of Bacteroides fragilis to the prevention and treatment of aquatic pathogens.
  • Aquatic probiotics products are common with Bacillus subtilis, Bacillus licheniformis, and Bacillus cereus, and other types of bacteria are rare, and different species of probiotics need to be added;
  • the technical problem to be solved by the present invention is to provide a Bacteroides fragilis application in anti-aquatic pathogenic bacteria, including the application of Bacteroides fragilis in preparing an antibacterial agent for aquatic pathogenic bacteria, and a pharmaceutical composition and feed containing the Bacteroides fragilis additive.
  • the present invention provides an application of Bacteroides fragilis in the preparation of an antibacterial agent for aquatic pathogenic bacteria.
  • Bacteroides fragilis comprises live Bacteroides fragilis, inactivated Bacteroides fragilis, Bacteroides fragilis lysate and/or Bacteroides fragilis culture supernatant.
  • the aquatic pathogen is Vibrio parahaemolyticus, Vibrio varius, Vibrio harveyi, Vibrio anguillarum or Pseudomonas aeruginosa.
  • Bacteroides fragilis is Bacteroides fragilis ZY-312 with the accession number CGMCC No. 10685, Bacteroides fragilis Bd312 with the accession number CGMCC NO. 7280 or the Bacteroides fragilis standard strain ATCC25285.
  • the present invention also provides a pharmaceutical composition for combating aquatic pathogenic bacteria, wherein the pharmaceutical composition contains a pharmaceutically effective amount of Bacteroides fragilis.
  • Bacteroides fragilis comprises a Bacteroides fragilis viable cell, an inactivated Bacteroides fragilis, a Bacteroides fragilis lysate, and/or a Bacteroides fragilis culture supernatant.
  • Bacteroides fragilis is Bacteroides fragilis ZY-312 with the accession number CGMCC No. 10685, Bacteroides fragilis Bd312 with the accession number CGMCC NO. 7280 or the Bacteroides fragilis standard strain ATCC25285.
  • the present invention also provides a feed additive for use against aquatic pathogenic bacteria, wherein the feed additive contains Bacteroides fragilis.
  • Bacteroides fragilis comprises a Bacteroides fragilis viable cell, an inactivated Bacteroides fragilis, a Bacteroides fragilis lysate, and/or a Bacteroides fragilis culture supernatant.
  • Bacteroides fragilis is a Bacteroides fragilis ZY-312 with a deposit number of CGMCC No. 10685 and a Bacteroides Bd312 with a deposit number of CGMCC No. 7280 (deposit time: March 12, 2013 ) or Bacteroides fragilis standard strain ATCC25285.
  • the invention detects and identifies the action of Bacteroides fragilis in various disease models, and proves that Bacteroides fragilis has a strong inhibitory effect on aquatic pathogenic bacteria.
  • Bacteroides fragilis has strong inhibitory effects on aquatic pathogenic bacteria such as Vibrio parahaemolyticus, Vibrio cholerae, Vibrio harveyi, Vibrio anguillarum or Pseudomonas aeruginosa, does not produce drug resistance, and is safe and non-toxic.
  • the invention provides a new choice for inhibiting aquatic pathogenic bacteria and has broad application prospects.
  • Fig. 1 is a view showing the morphology of Bacteroides fragilis (oil mirror, 1000 ⁇ ) according to an embodiment of the present invention.
  • Bacteroides fragilis ZY-312 was deposited with the China General Microorganisms Collection and Management Center (CGMCC) on April 2, 2015, and its deposit number is CGMCC No.10685.
  • the deposit address is No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing.
  • Bacteroides fragilis Bd312 was deposited with the General Microbiology Center (CGMCC) of the China Microbial Culture Collection Management Committee on March 12, 2013.
  • the deposit number is CGMCC NO.7280, and the deposit address is Beichen West Road, Chaoyang District, Beijing. No. 3 on the 1st.
  • Fig. 1 is a view showing the morphology of Bacteroides fragilis (oil mirror, 1000 ⁇ ) according to an embodiment of the present invention.
  • the invention provides an application of Bacteroides fragilis in preparing an antibacterial agent for aquatic pathogenic bacteria.
  • the Bacteroides fragilis includes live Bacteroides fragilis, inactivated Bacteroides fragilis, Bacteroides fragilis lysate and/or Bacteroides fragilis culture supernatant.
  • the aquatic pathogenic bacteria are Vibrio parahaemolyticus, Vibrio varius, Vibrio harveyi, Vibrio anguillarum or Pseudomonas aeruginosa.
  • Bacteroides fragilis is preferably Bacteroides fragilis ZY-312 with the accession number CGMCC No. 10685.
  • Bacteroides fragilis ZY-312 was deposited with the China General Microorganisms Collection and Management Center (CGMCC) on April 2, 2015, and its deposit number is CGMCC No.10685.
  • the deposit address is Beichen West Road, Chaoyang District, Beijing. No. 3 on the 1st.
  • the present invention also provides a pharmaceutical composition for combating aquatic pathogenic bacteria, which comprises a pharmaceutically effective amount (10 6 - 10 10 CFU, preferably 10 9 CFU) of Bacteroides fragilis.
  • the Bacteroides fragilis comprises a Bacteroides fragilis living organism, an inactivated Bacteroides fragilis, a Bacteroides fragilis lysate and/or a Bacteroides fragilis culture supernatant.
  • the Bacteroides fragilis is Bacteroides fragilis ZY-312 with the accession number CGMCC No. 10685.
  • the present invention also provides a feed additive for use against aquatic pathogenic bacteria, the feed additive comprising Bacteroides fragilis.
  • the Bacteroides fragilis includes live Bacteroides fragilis, inactivated Bacteroides fragilis, Bacteroides fragilis lysate, and/or Bacteroides fragilis culture supernatant.
  • the Bacteroides fragilis is a Bacteroides fragilis deposited under the accession number CGMCC No. 10685. The invention is further illustrated by the following examples.
  • Step 1 Take a freeze-preserved strain (ZY-312, Bd-312, ATCC25285 the same method), add 200 ⁇ L TSB medium, reconstitute, draw 20 ⁇ L blood plate, and anaerobic tank gas control system after pumping Analyzed in a biochemical incubator at 37 ° C for 48 h;
  • Step 2 Pick up the monoclonal colonies into 10 mL TSB medium, add 5% (v/v) peptide bovine serum, anaerobic culture for 12 h at 37 ° C;
  • Step 3 Take 1 bottle of 500mL TSB medium, add 5% (v / v) peptide bovine serum, access 1% (v / v) strain, 37 ° C, anaerobic culture for 48h;
  • Step 4 The bacteria solution was centrifuged at 6000 rpm for 10 min. Wash twice with physiological saline, and finally reconstitute the bacterial sludge with physiological saline for use and count the viable bacteria.
  • Step 5 Staining microscopy, using Gram staining, observed under oil microscope, is Gram-negative bacilli (see Figure 1).
  • Step 2 Take 200 ⁇ L of the culture solution, centrifuge at 6000-8000 rpm for 3-5 min at room temperature, discard the supernatant, and resuspend the pellet with 200 ⁇ L of sterile physiological saline;
  • Step 3 Vibrio parahaemolyticus, Vibrio harveyi, Vibrio harveyi, Vibrio anguillarum or Pseudomonas aeruginosa suspension were separately applied to TSA solid medium plates and fixed at 28 ° C for 2-3 h.
  • Step 2 Incubate at 28-30 ° C for 2-3 h. After the seed solution is absorbed by the medium, incubate in an incubator at 28 ° C for 24 to 48 hours.
  • the culture method of Bacteroides fragilis ZY-312 is the same as in Example 1.
  • Step 1 Take a lyophilized strain, add 200 ⁇ L of TSB medium, reconstitute, pipette 20 ⁇ L of blood plate, and ventilate the anaerobic tank gas control system at 37 ° C in anaerobic incubator for 48 h.
  • Step 2 Pick up the monoclonal colonies into 10 mL TSB medium, add 5% (v/v) peptide bovine serum, anaerobic culture for 12 h at 37 ° C;
  • Step 3 Take 1 bottle of 500mL TSB medium, add 5% (v / v) peptide bovine serum, access 1% (v / v) strain, 37 ° C, anaerobic culture for 48h;
  • Step 4 The bacteria solution was centrifuged, centrifuged with a centrifuge, and centrifuged at 6000 rpm for 10 minutes. Wash twice with physiological saline, and finally reconstitute the bacterial sludge with physiological saline for use and count the viable bacteria.
  • the spray-drying treatment was carried out at a temperature of 65 ° C using a spray dryer to obtain dried inactivated cells.
  • 1 g of the bacterial powder was dissolved in 100 mL of physiological saline.
  • the culture liquid of ZY-312 was treated by ultrasonic sonication with a sonicator, and it was broken for 2 seconds, stopped for 5 seconds, and continued for 20 minutes to obtain the Bacteroides fragilis lysate.
  • ZY-312 cultured the bacterial liquid, centrifuged with a centrifuge, centrifuged at 6000 rpm, 10 min, 4 ° C, and the supernatant was centrifuged to obtain a culture supernatant of Bacteroides fragilis.
  • Vibrio parahaemolyticus Vibrio harveyi
  • Vibrio harveyi Vibrio anguillarum or Pseudomonas aeruginosa were respectively applied to TSA solid medium at 28 ° C, and fixed for 2-3 h.
  • Bacteroides fragilis has obvious antibacterial activity against Vibrio parahaemolyticus, Vibrio varius, Vibrio harveyi, Vibrio anguillarum or Pseudomonas aeruginosa.
  • the living cells, inactivated cells, lysate and culture supernatant can be used for the prevention and control of aquaculture diseases and the development of new antibacterial substances, and have good application prospects.
  • Bacteroides fragilis acts on aquatic pathogenic bacteria such as Vibrio parahaemolyticus, Vibrio harveyi, Vibrio harveyi, Vibrio anguillarum or Pseudomonas aeruginosa. They all have strong inhibitory effects, no drug resistance, and are safe and non-toxic. Meanwhile, pharmaceutical compositions and feed additives for anti-aquatic pathogens containing Bacteroides fragilis have the same or similar effects.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Animal Husbandry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

一种脆弱拟杆菌在抗水产病原菌中的应用，包括脆弱拟杆菌在制备用于水产病原菌的抗菌药物中的应用及含有该脆弱拟杆菌的药物组合物及饲料添加剂。所述脆弱拟杆菌包括脆弱拟杆菌活菌体、灭活脆弱拟杆菌、脆弱拟杆菌裂解物和/或脆弱拟杆菌培养上清液。通过实验证明，脆弱拟杆菌对水产病原菌如副溶血弧菌、灿烂弧菌、哈氏弧菌、鳗弧菌或铜绿假单胞菌均具有较强的抑制效果，不产生耐药性，且安全无毒。同时，含有脆弱拟杆菌的用于抗水产病原菌的药物组合物、饲料添加剂，也具有相同或相似的作用。

Description

脆弱拟杆菌在抗水产病原菌中的应用 技术领域
本发明涉及微生物技术领域，特别是脆弱拟杆菌在水产养殖中的应用，具体为脆弱拟杆菌在抗水产病原菌中的应用。
背景技术
随着我国水产养殖业的不断发展。工厂化、高密度养殖造成的病害问题日益突出。每年因水产病害造成的损失多达数百亿元。而治疗水产动物的疾病，常规仍广泛采用化学治疗法，抗生素的滥用使水体细菌产生抗药性及药物残留，间接危害了人类的健康。因此，越来越多的专家开始关注利用自然环境中有益微生物对水产养殖环境的生物修复，以此来取代抗生素的使用，这样不仅节约了费用，还不会产生二次污染，而且还能将剩余饵料、排泄物及其他有害物质分解转化，使水质保持良好的状态，使养殖生物处于健康水平。
因此，有益微生物对水产养殖环境的生物修复技术的研究和开发具有极其广阔的前景，在水产养殖领域的应用也会越来越广泛，同时带来更大的经济效益和社会效益。随着规模化、集约化水产养殖业的迅速发展，水产养殖病害频繁发生，为了控制疾病，一些抗生素药物在水产养殖中被广泛使用和滥用，不仅造成环境中药物残留、细菌耐药性增加，而且由于水体环境的流动性，耐药基因更容易水平转移，造成更多耐药株的出现。为了应对耐药性，养殖中不得不加大用量并不断更换药物种类，进而造成恶性循环。另一方面药物的大量使用，药物在水产动物体内残留造成的食品安全问题也日益引起关注。为了应对这些问题，采用替代的生物防治措施成为当前水产养殖的热点，其中益生菌的应用在水产养殖中越来越受到重视，它们不仅具有抑制细菌性病原的作用，还具有促进水产养殖动物生长、改善免疫等作用。
益生菌(Probiotics)是一类对宿主有益的活性微生物，是定植于人体或动物肠道、生殖系统内，能产生确切健康功效从而改善宿主微生态平衡、发挥有益作用的活性有益微生物的总称。其主要通过改善宿主肠道微生物菌群的平衡而发挥作用。它具有改善肠道菌群结构，抑制病原菌，生成营养物质，提高机体免疫力，消除致癌因子，降低胆固醇和血压，改善乳糖消化性等功能。Fuller 于1989年首次给益生菌下定义：“益生菌是通过改善肠道菌群平衡而对宿主健康产生有益作用的活菌添加剂”。
人类生活中早已广泛应用的益生菌包括醋酸梭菌、乳酸菌、双歧杆菌、嗜酸乳杆菌、放线菌、酵母菌等。随着微生物防害方法的发展，特别是益生菌在取代传统抗生素的使用的前景，使得益生菌及其制剂越来越多地被应用于水产养殖业。目前水产养殖类的益生菌及其制剂主要分为两类：
1、单一制剂，如酵母菌、光合细菌、乳酸菌、乳酸杆菌、乳酸乳球菌、荧光假单胞菌、芽孢杆菌等；
2、复合制剂，如美菌方、复合型活性生物净水剂等，主要有硝化细菌和反硝化细菌、枯草杆菌、乳酸杆菌、双歧杆菌、假单胞菌、粪链球菌、酵母菌等菌株组成。该类益生菌群由定向筛选的有益菌株配合而成，能够改善水产动物体内的微生态平衡，刺激机体的免疫系统，拮抗致病微生物，降解有机废物，从而减少疾病发生，促进水产动物生长发育，改善养殖生态环境。
大量研究与实践证明，益生菌在水产养殖的应用中起到了良好的效果，如从虾等动物体内分离得到的多株益生菌，从而制成的微生物复合菌液可以改良底质，稳定水质，是保证养殖成功的重要技术。由于没有再施用化学药剂，因而生产出来的水产品是比较完全和无污染的绿色食品，并可避免水产品产生抗药性。多年连续使用菌液的水体必定能形成有效微生物菌群的生态优势，达到水环境的良性循环，保证对水产品养殖的持续发展。
脆弱拟杆菌是一种专性厌氧细菌，依培养基的不同和生长阶段的不同，菌体形态呈现多形性，一般条件下菌体为杆状、两端钝圆、着色深，中间色浅且不均匀，有荚膜、无芽胞、无动力，有些有空泡，菌体长短不一。脆弱拟杆菌作为人及动物肠道正常菌群的一部分，主要存在于结肠中。此外，呼吸道、胃肠道及泌尿生殖道粘膜也可定植生长。脆弱拟杆菌作为一种条件致病菌，当宿主粘膜受损时，可侵犯粘膜下层，引起感染，也可经血液流动，引起身体其它器官，如肠道、腹腔、肝、肺、脑组织、软组织、骨髓等的化脓性感染并伴发脓肿。
本领域已经对脆弱拟杆菌进行了大量研究。张季阶从发育良好的婴儿或低龄动物肠道中分离出一种拟杆菌菌株BF839，将其制成活菌制剂后能够增加儿童生长发育，对防治急慢性肠炎、菌群失调、上呼吸道感染和神经官能症等较 好疗效(参见公开号为CN1056314A的中国发明专利申请；及：张季阶，等.脆弱拟杆菌(BF839)菌液的临床应用研究.中国生物制品学杂志，1995年，第8卷，第2期，第63-65页)。智发朝等在2012年从婴儿粪便中分离出一种具有益生菌特性的脆弱拟杆菌菌株(保藏号为CGMCC NO.7280)，可用于治疗炎症性肠病、腹泻等(参见公开号为CN103146620A，CN103142658A及CN103156888A的中国发明专利申请)；此外，经对该菌株的进一步鉴定，发现该菌株(称为Bd312)在细菌形态、培养特性、生理生化反应结果与脆弱拟杆菌相似，经BLASTN序列比对，所分离菌株与脆弱拟杆菌标准株ATCC25285同源性达99％，药敏实验提示，菌株Bd312对头孢拉定、阿莫西林、庆大霉素、磺胺甲嗯唑、甲氧苄啶不敏感，急慢性毒性试验提示无毒性(参见：刘洋洋，等.健康婴儿体内的无毒脆弱拟杆菌的分离及鉴定.中华医学杂志，2014年，第94卷，第30期，第2372-2374页)。但是目前尚无脆弱拟杆菌应用于水产病原菌防治的报道。
市场上水产用益生菌产品，名目繁多，层出无穷，但是概括起来存在以下问题：
(1)水产益生菌产品以枯草芽孢杆菌、地衣芽孢杆菌、蜡样芽孢杆菌为常见，少见其它类型细菌，有待增加不同种属益生菌；
(2)常见水产益生菌产品中菌株抑菌效果不明确，而抑菌效果是评价益生菌的核心指标。
发明内容
本发明所要解决的技术问题是提供一种脆弱拟杆菌在抗水产病原菌中的应用，包括脆弱拟杆菌在制备用于水产病原菌的抗菌药物中的应用及含有该脆弱拟杆菌的药物组合物及饲料添加剂。
为了实现上述目的，本发明提供了一种脆弱拟杆菌在制备用于水产病原菌的抗菌药物中的应用。
上述的应用，其中，所述脆弱拟杆菌包括脆弱拟杆菌活菌体、灭活脆弱拟杆菌、脆弱拟杆菌裂解物和/或脆弱拟杆菌培养上清液。
上述的应用，其中，所述水产病原菌为副溶血弧菌、灿烂弧菌、哈氏弧菌、鳗弧菌或铜绿假单胞菌。
上述的应用，其中，所述脆弱拟杆菌为保藏号为CGMCC No.10685的脆弱拟杆菌ZY-312、保藏号为CGMCC NO.7280的脆弱拟杆菌Bd312或脆弱拟杆菌标准株ATCC25285。
为了更好地实现上述目的，本发明还提供了一种用于抗水产病原菌的药物组合物，其中，所述药物组合物含有药学有效剂量的脆弱拟杆菌。
上述的药物组合物，其中，所述脆弱拟杆菌包括脆弱拟杆菌活菌体、灭活脆弱拟杆菌、脆弱拟杆菌裂解物和/或脆弱拟杆菌培养上清液。
上述的药物组合物，其中，所述脆弱拟杆菌为保藏号为CGMCC No.10685的脆弱拟杆菌ZY-312、保藏号为CGMCC NO.7280的脆弱拟杆菌Bd312或脆弱拟杆菌标准株ATCC25285。
为了更好地实现上述目的，本发明还提供了一种用于抗水产病原菌的饲料添加剂，其中，所述饲料添加剂含有脆弱拟杆菌。
上述的饲料添加剂，其中，所述脆弱拟杆菌包括脆弱拟杆菌活菌体、灭活脆弱拟杆菌、脆弱拟杆菌裂解物和/或脆弱拟杆菌培养上清液。
上述的饲料添加剂，其中，所述脆弱拟杆菌为保藏号为CGMCC No.10685的脆弱拟杆菌ZY-312、保藏号为CGMCC NO.7280的脆弱拟杆菌Bd312(保藏时间：2013年3月12日)或脆弱拟杆菌标准株ATCC25285。
本发明的技术效果在于：
本发明通过在多种疾病模型中对脆弱拟杆菌的作用进行检测和鉴定，证明脆弱拟杆菌对水产病原菌具有较强的抑制效果。脆弱拟杆菌对水产病原菌如副溶血弧菌、灿烂弧菌、哈氏弧菌、鳗弧菌或铜绿假单胞菌均具有较强的抑制效果，不产生耐药性，且安全无毒。本发明为抑制水产病原菌提供了新的选择，具有广阔的应用前景。
以下结合附图和具体实施例对本发明进行详细描述，但不作为对本发明的限定。
附图说明
图1为本发明一实施例的脆弱拟杆菌形态图(油镜、1000×)。
脆弱拟杆菌(Bacteroides fragilis)ZY-312于2015年4月2日保藏于中国普通微生物菌种保藏管理中心(CGMCC)，其保藏编号为CGMCC No.10685， 保藏地址为北京市朝阳区北辰西路1号院3号。
脆弱拟杆菌(Bacteroides fragilis)Bd312于2013年3月12日保藏于中国微生物菌种保藏管理委员会普通微生物中心(CGMCC)，其保藏编号为CGMCC NO.7280，保藏地址为北京市朝阳区北辰西路1号院3号。
具体实施方式
下面结合附图对本发明的结构原理和工作原理作具体的描述：
参见图1，图1为本发明一实施例的脆弱拟杆菌形态图(油镜、1000×)。本发明提供一种脆弱拟杆菌在制备用于水产病原菌的抗菌药物中的应用。其中，所述脆弱拟杆菌包括脆弱拟杆菌活菌体、灭活脆弱拟杆菌、脆弱拟杆菌裂解物和/或脆弱拟杆菌培养上清液等。所述水产病原菌为副溶血弧菌、灿烂弧菌、哈氏弧菌、鳗弧菌或铜绿假单胞菌。本实施例中，所述脆弱拟杆菌优选为保藏号为CGMCC No.10685的脆弱拟杆菌ZY-312。脆弱拟杆菌(Bacteroides fragilis)ZY-312于2015年4月2日保藏于中国普通微生物菌种保藏管理中心(CGMCC)，其保藏编号为CGMCC No.10685，保藏地址为北京市朝阳区北辰西路1号院3号。
本发明还提供了一种用于抗水产病原菌的药物组合物，所述药物组合物含有药学有效剂量(106-1010CFU，优选109CFU)的脆弱拟杆菌。其中，所述脆弱拟杆菌包括脆弱拟杆菌活菌体、灭活脆弱拟杆菌、脆弱拟杆菌裂解物和/或脆弱拟杆菌培养上清液。所述脆弱拟杆菌为保藏号为CGMCC No.10685的脆弱拟杆菌ZY-312。
本发明还提供了一种用于抗水产病原菌的饲料添加剂，所述饲料添加剂含有脆弱拟杆菌。所述脆弱拟杆菌包括脆弱拟杆菌活菌体、灭活脆弱拟杆菌、脆弱拟杆菌裂解物和/或脆弱拟杆菌培养上清液。所述脆弱拟杆菌为保藏号为CGMCC No.10685的脆弱拟杆菌。下面通过多个实施例对本发明进一步予以说明。
实施例1脆弱拟杆菌ZY-312培养
试剂和仪器如下表所述：
Figure PCTCN2016092384-appb-000001
Figure PCTCN2016092384-appb-000002
培养方法
步骤1：取一支冻干保存菌种(ZY-312、Bd-312、ATCC25285方法相同)，加入200μL TSB培养基，复溶，吸取20μL血平皿划线，厌氧罐气体控制系统抽气后在生化培养箱中37℃、厌氧培养48h；
步骤2：挑取单克隆菌落接入10mL TSB培养基，加入5％(v/v)肽牛血清，37℃、厌氧培养12h；
步骤3：取1瓶500mL TSB培养基，分别加入5％(v/v)肽牛血清，接入1％(v/v)菌种，37℃、厌氧培养48h；
步骤4：取菌液离心，6000rpm、10min。用生理盐水洗涤2次，最后用生理盐水复溶菌泥备用并进行活菌计数。
步骤5：染色镜检，采用革兰氏染色法，油镜下观察，为革兰氏阴性杆菌(参见图1)。
实施例2脆弱拟杆菌对水产病原菌的抑制作用
1、病原菌平板制备
步骤1：将副溶血弧菌、灿烂弧菌、哈氏弧菌、鳗弧菌或铜绿假单胞菌用TSB液体培养基于28℃培养至OD600＝0.8-1.0；
步骤2：取200μL培养液，6000-8000rpm室温离心3-5min，弃上清，沉淀用200μL无菌生理盐水重新悬浮；
步骤3：将副溶血弧菌、灿烂弧菌、哈氏弧菌、鳗弧菌或铜绿假单胞菌悬浮液分别涂布在TSA固体培养基平皿，于28℃分别固定2-3h。
2、点种
步骤1：取培养至OD600＝0.8-1.0的ZY-312、Bd312或ATCC25285培养 液(经过病原菌平板制备的步骤2洗涤、重悬)、生理盐水各20μL，分别点在涂满病原菌的平板上(即上述步骤3获得的TSA固体培养基平皿)；
步骤2：在28-30℃培养2-3h，待点种液被培养基吸收后，置于28℃的培养箱中倒置过夜培养24-48h。
3、结果
对照PBS的结果，观察脆弱拟杆菌在各病原菌平板上的生长及抑菌圈的产生情况。如下表所示，发现脆弱拟杆菌对于所检测的细菌，都产生了明显的抑菌圈。而PBS则未见明显的抑菌圈产生。
脆弱拟杆菌与PBS对水产病原菌的抑制作用对照表
Figure PCTCN2016092384-appb-000003
其中，“﹢﹢﹢”表示抑菌圈的直径为0.8-1.3cm；“﹢﹢”表示抑菌圈的直径为0.6-0.8cm；“﹢”表示抑菌圈的直径为0.4-0.6cm；“-”表示无抑菌圈产生。上述符号在本发明其他实施例中表达同样的含义。
实施例3脆弱拟杆菌ZY-312对水产病原菌的抑制作用
1、培养方法
脆弱拟杆菌ZY-312培养方法同实施例1。
2、样品准备
1)脆弱拟杆菌ZY-312活菌体的制备
步骤1：取一支冻干保存菌种，加入200μL TSB培养基，复溶，吸取20μL血平皿划线，厌氧罐气体控制系统抽气后在生化培养箱中37℃、厌氧培养48h；
步骤2：挑取单克隆菌落接入10mL TSB培养基，加入5％(v/v)肽牛血清，37℃、厌氧培养12h；
步骤3：取1瓶500mL TSB培养基，分别加入5％(v/v)肽牛血清，接入1％(v/v)菌种，37℃、厌氧培养48h；
步骤4：取菌液离心，，用离心机进行离心，离心条件6000rpm、10min。 用生理盐水洗涤2次，最后用生理盐水复溶菌泥备用并进行活菌计数。
2)脆弱拟杆菌灭活菌体
采用喷雾干燥机，在温度65℃进行喷雾干燥法处理，获得干燥灭活菌体。取1g菌粉溶解于100mL生理盐水中。
3)脆弱拟杆菌裂解液
ZY-312培养菌液，采用超声破碎仪进行超声破碎法处理，破2秒，停5秒，持续20分钟，获得脆弱拟杆菌裂解液。
4)脆弱拟杆菌培养上清液
ZY-312培养菌液，用离心机进行离心，离心条件为6000rpm、10min、4℃，离心取上清，获得脆弱拟杆菌培养上清液。
3、抑菌试验
1)病原菌平板制备
将副溶血弧菌、灿烂弧菌、哈氏弧菌、鳗弧菌或铜绿假单胞菌用TSB液体培养基于28℃培养至OD600＝0.8-1.0，取200μL培养液，6000-8000rpm室温离心3-5min，弃上清，沉淀用200μL无菌PBS重新悬浮。将副溶血弧菌、灿烂弧菌、哈氏弧菌、鳗弧菌或铜绿假单胞菌悬浮液分别涂布在TSA固体培养基于28℃，分别固定2-3h。
2)点种
取培养至OD600＝0.8-1.0的ZY-312活菌体(洗涤、重悬)、灭活菌体、裂解液、培养上清、PBS各20μL，分别点在涂满病原菌的上述平板上。28-30℃培养2-3h，待点种液被培养基吸收后，置于28℃的培养箱中倒置过夜培养24-48h。
4、结果
对照PBS的结果，观察脆弱拟杆菌在各病原菌平板上的生长及抑菌圈的产生情况。如下表所示，发现脆弱拟杆菌活菌体、灭活菌体、裂解液、培养上清对于所检测的细菌，都产生了明显的抑菌圈。而PBS则未见明显的抑菌圈产生。
脆弱拟杆菌ZY-312及PBS对水产病原菌的抑制作用对照表
Figure PCTCN2016092384-appb-000004
Figure PCTCN2016092384-appb-000005
由上述结果可知，脆弱拟杆菌对水产病原菌的副溶血弧菌、灿烂弧菌、哈氏弧菌、鳗弧菌或铜绿假单胞菌均具有明显抑菌作用。其活菌体、灭活菌体、裂解液、培养上清均可用于水产养殖类病害的防控及新型抗菌物质的开发，具有较好的应用前景。
本发明的脆弱拟杆菌在水产养殖中的应用，通过实验第一次证明，脆弱拟杆菌对水产病原菌如副溶血弧菌、灿烂弧菌、哈氏弧菌、鳗弧菌或铜绿假单胞菌均具有较强的抑制效果，不产生耐药性，且安全无毒。同时，含有脆弱拟杆菌的用于抗水产病原菌的药物组合物、饲料添加剂，也具有相同或相似的作用。
当然，本发明还可有其它多种实施例，在不背离本发明精神及其实质的情况下，熟悉本领域的技术人员当可根据本发明作出各种相应的改变和变形，但这些相应的改变和变形都应属于本发明所附的权利要求的保护范围。

Claims (10)

  1. 一种脆弱拟杆菌在制备用于水产病原菌的抗菌药物中的应用。
  2. 如权利要求1所述的应用，其特征在于，所述脆弱拟杆菌包括脆弱拟杆菌活菌体、灭活脆弱拟杆菌、脆弱拟杆菌裂解物和/或脆弱拟杆菌培养上清液。
  3. 如权利要求1所述的应用，其特征在于，所述水产病原菌为副溶血弧菌、灿烂弧菌、哈氏弧菌、鳗弧菌或铜绿假单胞菌。
  4. 如权利要求1、2或3所述的应用，其特征在于，所述脆弱拟杆菌为保藏号为CGMCC No.10685的脆弱拟杆菌ZY-312、保藏号为CGMCC NO.7280的脆弱拟杆菌Bd312或脆弱拟杆菌标准株ATCC25285。
  5. 一种用于抗水产病原菌的药物组合物，其特征在于，所述药物组合物含有药学有效剂量的脆弱拟杆菌。
  6. 如权利要求5所述的药物组合物，其特征在于，所述脆弱拟杆菌包括脆弱拟杆菌活菌体、灭活脆弱拟杆菌、脆弱拟杆菌裂解物和/或脆弱拟杆菌培养上清液。
  7. 如权利要求5或6所述的药物组合物，其特征在于，所述脆弱拟杆菌为保藏号为CGMCC No.10685的脆弱拟杆菌ZY-312、保藏号为CGMCC NO.7280的脆弱拟杆菌Bd312或脆弱拟杆菌标准株ATCC25285。
  8. 一种用于抗水产病原菌的饲料添加剂，其特征在于，所述饲料添加剂含有脆弱拟杆菌。
  9. 如权利要求8所述的饲料添加剂，其特征在于，所述脆弱拟杆菌包括脆弱拟杆菌活菌体、灭活脆弱拟杆菌、脆弱拟杆菌裂解物和/或脆弱拟杆菌培养上清液。
  10. 如权利要求8或9所述的饲料添加剂，其特征在于，所述脆弱拟杆菌为保藏号为CGMCC No.10685的脆弱拟杆菌ZY-312、保藏号为CGMCC NO.7280的脆弱拟杆菌Bd312或脆弱拟杆菌标准株ATCC25285。
PCT/CN2016/092384 2015-10-29 2016-07-29 脆弱拟杆菌在抗水产病原菌中的应用 WO2017071346A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510727741.4 2015-10-29
CN201510727741.4A CN105434477B (zh) 2015-10-29 2015-10-29 脆弱拟杆菌在抗水产病原菌中的应用

Publications (1)

Publication Number Publication Date
WO2017071346A1 true WO2017071346A1 (zh) 2017-05-04

Family

ID=55545411

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/092384 WO2017071346A1 (zh) 2015-10-29 2016-07-29 脆弱拟杆菌在抗水产病原菌中的应用

Country Status (2)

Country Link
CN (1) CN105434477B (zh)
WO (1) WO2017071346A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106387314B (zh) * 2015-07-31 2020-11-06 广州普维君健药业有限公司 脆弱拟杆菌在动物养殖中的应用
CN105434477B (zh) * 2015-10-29 2019-03-05 广州普维君健药业有限公司 脆弱拟杆菌在抗水产病原菌中的应用
CN107625791A (zh) * 2016-07-18 2018-01-26 广州知易生物科技有限公司 脆弱拟杆菌在制备抑制艰难梭菌粘附的组合物中的应用
CN107629977A (zh) * 2016-07-18 2018-01-26 广州普维君健药业有限公司 脆弱拟杆菌在制备防治副溶血弧菌感染的组合物中的应用
CN109793761B (zh) * 2017-11-17 2021-03-05 瑞微（深圳）生物科技有限公司 一种用于增强t细胞免疫功能的组合物及其制备方法
CN109908184A (zh) * 2017-12-12 2019-06-21 中山大学 脆弱拟杆菌在制备用于诱导γδT细胞增殖和/或积累的药物中的应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1056314A (zh) * 1990-05-03 1991-11-20 张李阶 一株有益菌株及其应用
CN101845425A (zh) * 2010-05-25 2010-09-29 中国人民解放军军事医学科学院野战输血研究所 一种α-半乳糖苷酶及其表达、纯化方法
JP2012180289A (ja) * 2011-02-28 2012-09-20 Morinaga Milk Ind Co Ltd 抗菌剤
CN103142658A (zh) * 2013-03-18 2013-06-12 广州知光生物科技有限公司 脆弱拟杆菌在制备治疗急性放射性肠炎组合物中的应用
CN103146620A (zh) * 2013-03-25 2013-06-12 广州知光生物科技有限公司 具有益生菌特性的脆弱拟杆菌
CN103156888A (zh) * 2013-03-18 2013-06-19 广州知光生物科技有限公司 脆弱拟杆菌在制备治疗炎症性肠病组合物中的应用
CN105434477A (zh) * 2015-10-29 2016-03-30 广州知易生物科技有限公司 脆弱拟杆菌在抗水产病原菌中的应用
CN105434476A (zh) * 2015-10-29 2016-03-30 广州知易生物科技有限公司 一种脆弱拟杆菌在预防和/或治疗炎症性肠病中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106399141B (zh) * 2015-07-31 2019-07-05 广州知易生物科技有限公司 一种脆弱拟杆菌及其应用

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1056314A (zh) * 1990-05-03 1991-11-20 张李阶 一株有益菌株及其应用
CN101845425A (zh) * 2010-05-25 2010-09-29 中国人民解放军军事医学科学院野战输血研究所 一种α-半乳糖苷酶及其表达、纯化方法
JP2012180289A (ja) * 2011-02-28 2012-09-20 Morinaga Milk Ind Co Ltd 抗菌剤
CN103142658A (zh) * 2013-03-18 2013-06-12 广州知光生物科技有限公司 脆弱拟杆菌在制备治疗急性放射性肠炎组合物中的应用
CN103156888A (zh) * 2013-03-18 2013-06-19 广州知光生物科技有限公司 脆弱拟杆菌在制备治疗炎症性肠病组合物中的应用
CN103146620A (zh) * 2013-03-25 2013-06-12 广州知光生物科技有限公司 具有益生菌特性的脆弱拟杆菌
CN105434477A (zh) * 2015-10-29 2016-03-30 广州知易生物科技有限公司 脆弱拟杆菌在抗水产病原菌中的应用
CN105434476A (zh) * 2015-10-29 2016-03-30 广州知易生物科技有限公司 一种脆弱拟杆菌在预防和/或治疗炎症性肠病中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FENG, SHUZHEN ET AL.: "The Research Progress of Bacteroides Fragilis", ACTA MICROBIOLOGICA SINICA, vol. 42, no. 7, 20 July 2015 (2015-07-20), pages 1 366 - 1371, XP055361914, DOI: doi:10.13344/j.microbiol.china.140778 *

Also Published As

Publication number Publication date
CN105434477A (zh) 2016-03-30
CN105434477B (zh) 2019-03-05

Similar Documents

Publication Publication Date Title
WO2017071346A1 (zh) 脆弱拟杆菌在抗水产病原菌中的应用
WO2017020784A1 (zh) 一种脆弱拟杆菌及其应用
CN111534446A (zh) 罗伊氏乳杆菌及其应用
CN113846035B (zh) 一株缓解肠炎、脑膜炎和促进肠道发育的唾液乳杆菌及其应用
CN112625979B (zh) 一种对抗幽门螺杆菌的干酪乳杆菌及其应用
CN113122466B (zh) 粪肠球菌及其应用
CN114806978B (zh) 约氏乳杆菌sxdt-23及其应用
CN114292781B (zh) 一种长双歧杆菌sysu-02及其应用
CN113040390B (zh) 一株益生、耐盐约氏乳杆菌及其在畜禽水产养殖中防治病原菌的应用
Zhang et al. Screening and evaluation of lactic acid bacteria with probiotic potential from local Holstein raw milk
CN107949633B (zh) 鼠李糖乳杆菌、动物饲料及其组合物及无活性细胞生产法
CN112322553B (zh) 一种抗艰难梭菌的乳酸乳球菌及其应用
KR101201420B1 (ko) 신규 락토바실러스 존슨니 및 이를 포함하는 사료첨가제 조성물
CN116948920A (zh) 一株修复抗生素相关性腹泻导致的肠道菌群紊乱的乳酸片球菌及其应用
CN109576165B (zh) 一种贝酵母菌及其应用
CN115925832A (zh) 一种乳酸菌素及其在防控畜禽细菌感染的应用
KR100513168B1 (ko) 돼지 유행성 설사증 (PED) 코로나바이러스 및 유해 미생물 억제 활성을 가지는 신규 내 산성 엔테로코커스 훼카리스Probio-056 및 이를 함유하는 생균활성제
KR100513167B1 (ko) 가금티푸스 유발 살모넬라 갈리나룸 및 유해 병원성 미생물 생육 억제능을 갖는 신규 내산성 엔테로코커스 훼칼리스 Probio-053 및 이를 함유한 생균활성제
TWI600758B (zh) 具免疫調節機能的植物乳桿菌及其用途
Raju et al. Isolation, Characterization and Sequencing of Lactobacillus from the Oral and Fecal Samples of Healthy Dogs
CN115704002B (zh) 一种丁酸梭菌cc02001及其应用
CN117143782B (zh) 一种唾液链球菌嗜热亚种vb331及其应用
Ghaderian et al. Probiotic therapy, what is the most effective method for host protection against enteric pathogen
Mermouri et al. In vitro screening for probiotic potential of Lactobacillus strains isolated from algerian fermented products
CN114874952B (zh) 干酪乳杆菌hjd及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16858785

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16858785

Country of ref document: EP

Kind code of ref document: A1